PMEF
FATE icon

Point72 Middle East FZE’s Fate Therapeutics FATE Stock Holding History

Point72 Middle East FZE’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-44,767
Closed -$167K – 483
2023
Q4 		$167K Sell
44,767
-146,726
-77% -$346K 0.01% 1090
2023
Q3 		$406K Buy
191,493
+125,413
+190% +$415K 0.01% 860
2023
Q2 		$315K Buy
+66,080
New +$365K 0.01% 916
2023
Q1 		– Sell
-39,031
Closed -$394K – 1804
2022
Q4 		$394K Buy
+39,031
New +$733K 0.02% 820

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Middle East FZE's FATE Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Fate Therapeutics (FATE) in Q1 2024, closing a stake of 44,767 shares — an estimated $167K sold.

Point72 Middle East FZE first reported a position in FATE in Q4 2022 and held it in 4 quarters. The position peaked at $406K in Q3 2023. 167 funds tracked by Wall St. Rank hold FATE as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Fate Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 44,767 Fate Therapeutics shares in Q1 2024, an estimated $167K.
  • Point72 Middle East FZE first reported a position in Fate Therapeutics in Q4 2022 and held it in 4 quarters.
  • Point72 Middle East FZE's Fate Therapeutics position peaked at $406K in Q3 2023.
  • 167 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.